Fig. 1 · Structure

Documents & Downloads

Artemisinin

Cat. No. A10086 CAS 63968-64-9
Artemisinin and its derivatives are a group of drugs that possess the most rapid action of all current drugs against Plasmodium falciparum malaria.

In Stock

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

Artemisinin interacts with reduced heme in a cell-free assay, decreasing the 415 nm Soret absorbance and producing a peak at 476 nm. These spectral changes support heme-associated chemical reactivity; they do not identify a unique cellular target or quantify binding affinity. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Target & Activity

Target Activity Value
Plasmodium  

Cellular Effect

Cell Line Activity Value Description Reference
A-375 IC50 > 50 μM Antiproliferative activity against human A375 cells after 72 hrs by CCK-8 assay [PMID: 29597166]
A-375 IC50 > 50 μM Cytotoxicity against human A375 cells assessed as reduction in cell viability after 72 hrs by MTT assay [PMID: 29789258]
A-431 IC50 39.03 μM Antiproliferative activity against human A431 cells assessed as reduction in cell viability after 24 hrs by MTT assay [PMID: 31546197]
A549 IC50 > 300 μM Antiproliferative activity against human A549 cells assessed as cell growth inhibition by MTT assay [PMID: 31945642]
A549 IC50 > 50 μM Antiproliferative activity against human A549 cells after 72 hrs by CCK-8 assay [PMID: 29597166]
A549 IC50 > 50 μM Antiproliferative activity against human A549 cells measured after 48 hrs by MTT assay [PMID: 30837097]
A549 IC50 > 50 μM Cytotoxicity against human A549 cells assessed as reduction in cell viability after 72 hrs by MTT assay [PMID: 29789258]
A549 IC50 39.03 μM Antiproliferative activity against human A549 cells assessed as reduction in cell viability after 24 hrs by MTT assay [PMID: 31546197]
A549 IC50 9.85 μM Anticancer activity against human A549 cells assessed as cell growth inhibition measured for 72 hrs by MTT assay [PMID: 34303874]
ADR5000 cell line EC50 26.9 μM Cytotoxicity against human CEM/ADR5000 cells over-expressing P-gp assessed as reduction in cell viability after 72 hrs by resazurin dye based assay [PMID: 29887512]
BEAS-2B IC50 7.53 μM Anticancer activity against human BEAS-2B cells assessed as cell growth inhibition measured for 72 hrs by MTT assay [PMID: 34303874]
BT-549 IC50 40 μM Antiproliferative activity against human BT-549 cells assessed as cell growth inhibition measured after 72 hrs by SRB assay [PMID: 27010926]
CCRF-CEM EC50 36.9 μM Cytotoxicity against human CCRF-CEM cells assessed as reduction in cell viability after 72 hrs by resazurin dye based assay [PMID: 29887512]
COLO 205 IC50 39.03 μM Antiproliferative activity against human COLO205 cells assessed as reduction in cell viability after 24 hrs by MTT assay [PMID: 31546197]
HCT-116 IC50 > 50 μM Antiproliferative activity against human HCT116 cells after 72 hrs by CCK-8 assay [PMID: 29597166]
HCT-15 IC50 > 300 μM Antiproliferative activity against human HCT-15 cells assessed as cell growth inhibition by MTT assay [PMID: 31945642]
HEK293 IC50 > 120 nM Cytotoxicity against HEK293 cells by alamar blue assay [PMID: 27212070]
HEK293 CC50 > 26 μM Cytotoxicity against human HEK293 cells assessed as cell viability measured for 24 hrs by MTT assay [PMID: 34303874]
HepG2 CC50 > 30 μM Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by CellTiter-Glo assay [PMID: 33620219]
HepG2 IC50 > 300 μM Antiproliferative activity against human HepG2 cells assessed as cell growth inhibition by MTT assay [PMID: 31945642]

20 records · Scroll to view more

In Vitro Studies

In MOLT-4 leukemia cells, 40 µM artemisinin for 48 h had a modest effect on ATP-based viability. Co-treatment with the heme precursor ALA enhanced the effect, while the heme-synthesis inhibitor succinyl acetone prevented this enhancement. The findings are specific to this cellular design. [1]

In HT-22 cells, 25 µM artemisinin given for 12 h before a 12 h glutamate insult reduced loss of viability. Pretreatment shorter than 12 h did not protect cells. In the separate basal-exposure comparison, 6.25–50 µM did not cause detectable cytotoxicity, whereas 100 µM reduced viability after 24 h. [2]

Cell-free interaction with reduced heme

Biochemical assay · Reduced heme in a cell-free absorption assay [1]

Artemisinin changed the absorption spectrum of reduced heme. This is evidence of chemical interaction, not a binding-affinity measurement or proof of a unique intracellular target.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Heme absorption spectrum after addition of artemisininAbsorbance peak change Decrease at 415 nm; appearance of a peak at 476 nm[1]
Decrease in heme Soret absorbanceA415 reduction >20% at an artemisinin:heme molar ratio of 0.4:1 with 20 µM heme[1]

Literature-Reported Treatment Conditions

Treatment concentration
20 µM heme; artemisinin:heme molar-ratio series. Figure 4 labels ART:heme ratios of 0.8:1, 1.6:1 and 3.2:1.
Method
Cell-free absorbance measurement under dithionite-reducing conditions.
Vehicle
DMSO-containing phosphate buffer.
Reported limits
Reaction duration and replicate count for Figures 4–5 are not specified in the selected text. No IC50 or affinity constant was established.
Methods and source locations

Compound reported in the paper: Artemisinin; Compound label in the paper: ART

Published material and model only; no product-batch validation or clinical inference.

Methods: Chemicals and Heme Interaction Assay; Results: Spectrophotometric characterization and Sensitivity and specificity; Figures 4–5

Heme absorption spectrum after addition of artemisinin: Absorption spectroscopy with hemin reduced by dithionite; heme-only and hemin spectra shown in Figure 4. — Results: Spectrophotometric characterization of the Heme-Artemisinin interaction; Figure 4

Decrease in heme Soret absorbance: Absorption assay; Figure 5 compares ART, DHA, artesunate and amodiaquine. — Results: Sensitivity and specificity of the heme-artemisinin interaction; Figure 5

Heme-pathway modulation of artemisinin effects in MOLT-4 cells

Cell-based study · Human MOLT-4 lymphoblastoid leukemia cells [1]

Parent artemisinin had a modest effect on the ATP-based viability readout. Aminolevulinic acid enhanced the effect, and succinyl acetone prevented this enhancement.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Cellular ATP response to artemisinin and heme-pathway modifiersATP-based cell viability Artemisinin alone modestly reduced the readout; ALA enhanced the effect; ALA/SA returned the response toward artemisinin alone.[1]

Literature-Reported Treatment Conditions

Treatment concentration
40 µM artemisinin
Exposure duration
48 h
Method
Cell exposure followed by ATP measurement.
Vehicle
DMSO; equal-volume DMSO controls.
Co-treatment
Separate artemisinin-alone, artemisinin + 1 mM ALA, and artemisinin + 1 mM ALA + 0.5 mM SA conditions.
Reported limits
Final DMSO percentage and exact replicate count for Figure 8 are not stated in the selected material. No IC50 is reported for this design.
Methods and source locations

Compound reported in the paper: Artemisinin; Compound label in the paper: ART

Published material and model only; no product-batch validation or clinical inference.

Methods: Chemicals, Cell Culture and cytotoxicity assays, Statistical analysis; Results: HI HTS compound cytotoxicity and dependence upon heme synthesis; Figure 8

Cellular ATP response to artemisinin and heme-pathway modifiers: CellTiter-Glo ATP assay; matched DMSO, ALA and ALA/SA controls. — Results: HI HTS compound cytotoxicity and dependence upon heme synthesis, parent-artemisinin paragraphs; Figure 8

Exposure timing and protection from glutamate injury in HT-22 cells

Cell-based study · Mouse HT-22 hippocampal cell line [2]

Artemisinin pretreatment protected HT-22 cells from glutamate-associated loss of viability under the tested conditions. Protection depended on pretreatment duration, and 100 µM artemisinin alone reduced viability.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Viability after glutamate injuryCalcein-AM viability 25 µM artemisinin for 12 h before 12 h glutamate exposure was protective; no protection was reported with pretreatment shorter than 12 h.[2]
Viability after artemisinin aloneCalcein-AM viability No cytotoxic effect at 6.25–50 µM; reduced viability at 100 µM after 24 h.[2]

Literature-Reported Treatment Conditions

Treatment concentration
6.25, 12.5, 25, 50 or 100 µM artemisinin in the basal viability series; 25 µM in the pretreatment-time comparison.
Exposure duration
Basal exposure: 24 h. Protective condition: 12 h pretreatment followed by 12 h glutamate insult. Timing comparison includes 0, 1, 3, 6, 12 and 24 h pretreatment.
Method
Cell pretreatment and viability assay.
Co-treatment
Injury conditions used 6 mM glutamate; separate artemisinin-only and untreated controls.
Reported limits
Artemisinin solvent and final vehicle concentration are not reported in the selected procedures. Experiments were at least in triplicate; exact n per panel is unspecified. Whether artemisinin was removed before glutamate was not established.
Methods and source locations

Compound reported in the paper: Artemisinin; Compound label in the paper: ART

Published material and model only; no product-batch validation or clinical inference.

Experimental Procedures: Cell Culture, Cell Viability Assay, Statistical Analysis; Results: Artemisinin Pretreatment Reduced Glutamate-Induced Cytotoxicity in HT-22 Cells; Figure 1A–D

Viability after glutamate injury: Calcein-AM assay, normalized to control; Figure 1B–C identifies 6 mM glutamate. — Results first subsection; Figure 1B–C; Cell Viability Assay

Viability after artemisinin alone: Calcein-AM assay normalized to untreated control. — Results first subsection; Figure 1A

In Vivo Studies

A healthy-mouse comparison found no detectable serum artemisinin 60 min after a single oral 100 mg kg−1 pure-drug dose; the same nominal dose with mouse chow yielded 2.44 mg L−1. Each measurement used pooled blood from three mice, so variability could not be estimated. This result concerns exposure and does not establish efficacy. [3]

Effect of food matrix on oral artemisinin exposure

Animal study · Healthy mice; additional comparator cohorts of three mice per group, with pooled blood [3]

At 60 min, artemisinin was not detected after the pure-drug condition but was detected when the same nominal dose was given with mouse chow. This is a single-time-point exposure comparison, not an efficacy or complete pharmacokinetic study of pure artemisinin.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Serum artemisinin at 60 minConcentration Pure AN: 0 (Table 2; described as not detected); AN + chow: 2.44 mg L−1; untreated healthy control: 0.[3]

Conditions shared by the study groups

Route
Oral gavage
Frequency
Single administration
Treatment course
Blood collected 60 min after gavage.
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Pure artemisinin
100 mg kg−1 body weight
Untreated healthy mice, three pooled; comparison between pure AN with and without chow.Serum artemisinin reported as 0 mg L−1 at 60 min; described in the text as not detected.[3]
Artemisinin with mouse chow
100 mg kg−1 body weight
Untreated healthy mice, three pooled; comparison between pure AN with and without chow.Serum artemisinin 2.44 mg L−1 at 60 min.[3]
Pure artemisinin
Model: Healthy mice; three animals pooled per group.
Vehicle: DMSO and water; without mouse chow.
Reported limits: No SE calculated because blood was pooled. Vehicle proportions, chow quantity, and assay detection limit are not provided in the selected material. Strain/sex are not explicitly restated for these additional groups.
Artemisinin with mouse chow
Model: Healthy mice; three animals pooled per group.
Vehicle: DMSO and water; with mouse chow.
Reported limits: No SE calculated because blood was pooled. Vehicle proportions, chow quantity, and assay detection limit are not provided in the selected material. Strain/sex are not explicitly restated for these additional groups.
Methods and source locations

Compound reported in the paper: Artemisinin; Compound label in the paper: AN

Published material and model only; no product-batch validation or clinical inference.

Section 2.2: additional healthy serum comparisons; section 2.3: serum analysis; section 4.3: mouse-chow comparison; Table 2 and footnote a

Serum artemisinin at 60 min: GCMS with authentic standards; blood from three mice pooled per comparator group. — Table 2, healthy untreated, healthy + AN and healthy + chow + AN rows; footnote a; Results mouse-chow paragraph

Pure artemisinin · Section 2.2 additional healthy comparator sentences; Table 2 healthy comparator rows and footnote a

Artemisinin with mouse chow · Section 2.2 additional healthy comparator sentences; Table 2 healthy comparator rows and footnote a

Specifications

Manufacturer Adooq Bioscience
CAS Number 63968-64-9
Formula C15H22O5
Molecular Weight 282.3
Synonyms Coartem; Qinghaosu
SMILES
[H][C@]12[C@@H](C)C(O[C@@]3([H])[C@@]1(OO4)[C@](CC[C@]4(C)O3)([H])[C@H](C)CC2)=O

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 55 mg/mL (194.81 mM)
Water Insoluble
Ethanol 23 mg/mL (81.46 mM)

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Research References

  1. [1] Zhang S, Gerhard GS. Heme mediates cytotoxicity from artemisinin and serves as a general anti-proliferation target. PloS one (2009). PMID: 19862332 DOI: 10.1371/journal.pone.0007472 Source material
  2. [2] Lin SP, Li W, Winters A, et al. Artemisinin Prevents Glutamate-Induced Neuronal Cell Death Via Akt Pathway Activation. Frontiers in cellular neuroscience (2018). PMID: 29731711 DOI: 10.3389/fncel.2018.00108 Source material
  3. [3] Weathers PJ, Elfawal MA, Towler MJ, et al. Pharmacokinetics of artemisinin delivered by oral consumption of Artemisia annua dried leaves in healthy vs. Plasmodium chabaudi-infected mice. Journal of ethnopharmacology (2014). PMID: 24661969 DOI: 10.1016/j.jep.2014.03.037 Source material

Added to your cart

View Cart Checkout
Loading...